| Autor: |
Haoyuan Hong, Bin Luo, Yingying Qin, Sizhu Li, Zhigang Peng |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Bioengineered. 13(3) |
| ISSN: |
2165-5987 |
| Popis: |
About 40% of patients with diffuse large B-cell lymphoma (DLBCL) develop drug resistance after first-line chemotherapy, which remains a major cause of morbidity and mortality. The emergence of DLBCL drug resistance is mainly related to Adriamycin. Our previous research shows that Paclitaxel could be a potential therapeutic drug for the treatment of Adriamycin-resistant DLBCL. Based on the results of RNA-seq and integrated network analysis, we study the potential molecular mechanism of Paclitaxel in the treatment of Adriamycin-resistant DLBCL in multiple dimensions. A CCK-8 assay showed that the inhibitory effect of Paclitaxel on Pfeiffer and Pfeiffer/ADM (Adriamycin-resistant DLBCL cell lines) is significantly higher than that of Adriamycin ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
